CAMBRIDGE, Mass.--(BUSINESS WIRE)--EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced a strategic collaboration agreement with Abdul Latif Jameel Health, part of international diversified family business Abdul Latif Jameel. Through the agreement, Abdul Latif Jameel Health will become EQRx’s regulatory and commercial partner for aumolertinib and sugemalimab, if approved, in selected markets throughout the Middle East region, as well as in Turkey and all of Africa.
“It’s our joint mission with EQRx to change that, a mission that is aligned with the values of the Jameel Family.”
Tweet this
Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor, and sugemalimab, an anti-PD-L1 antibody, have both shown promising Phase 3 data for the treatment of patients with advanced non-small cell lung cancer (NSCLC).
“This strategic collaboration aims to expand the commercial reach of our lead oncology programs throughout the Middle East, Turkey and Africa and provide millions of people with access to affordable new cancer treatments,” said Melanie Nallicheri, chief executive officer of EQRx. “We are excited to partner with Abdul Latif Jameel Health which brings extensive regulatory and commercial expertise in these vast regions as we continue to work to create sustainable access to innovative medicines globally.”
“This agreement comes as we forge ahead in our mission...
[OSEN=Seon Mi-kyung Reporter] Rapper Yang Hong-won, who has sparked controversy over infidelity allegations just five days after his marriage, is drawing attention for reportedly singing his wife W...